Inozi-Co 300 mg/300 mg Tablet
PDF Leaflet Revision Date: 29 August 2023
Clinical Summary
Quick overview from the medicine insert
Indication
Prevention of active tuberculosis in high-risk adults with latent TB infection.
Dosage (summary)
Once weekly for 12 weeks; max 900 mg for both components based on weight.
Special Populations
- Elderly
- Hepatic impairment
- Renal impairment
Pregnancy & Breastfeeding
Not recommended during pregnancy; avoid breastfeeding.
Key Drug Interactions
- Protease inhibitors
- NNRTIs
- Hormonal contraceptives
- Digoxin
Contraindications
- Hypersensitivity
- Acute liver disease
- Severe renal failure
- Alcoholism
- Seizure disorders
Common side effects
- Nausea
- Headache
- Fatigue
- Skin reactions
Counselling Points
- Take with food
- Adhere to treatment regimen
- Monitor for liver function
- Avoid alcohol
Serious warnings
- Hepatotoxicity
- Hypersensitivity reactions
- Severe cutaneous adverse reactions
Important Disclaimer
The Inozi-Co 300 mg/300 mg Tablet professional information leaflet below is the property of Macleods Pharmaceuticals Sa and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
